Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women. After week 10, participants continued to receive prazosin or placebo in a double-blind fashion for an additional 16 weeks. The three primary outcome measures were the change in score from baseline to 10 weeks on the Clinician-Administered PTSD Scale (CAPS) item B2 ("recurrent distressing dreams"; scores range from 0 to 8, with higher scores indicating more frequent and more distressing dreams); the change in score from baseline to 10 weeks on the Pittsburgh Sleep Quality Index (PSQI; scores range from 0 to 21, with higher scores indicating worse sleep quality); and the Clinical Global Impression of Change (CGIC) score at 10 weeks (scores range from 1 to 7, with lower scores indicating greater improvement and a score of 4 indicating no change). RESULTS: A total of 304 participants underwent randomization; 152 were assigned to prazosin, and 152 to placebo. At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96). There were no significant differences in these measures at 26 weeks (a secondary outcome) or in other secondary outcomes. At 10 weeks, the mean difference between the prazosin group and the placebo group in the change from baseline in supine systolic blood pressure was a decrease of 6.7 mm Hg. The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo. CONCLUSIONS: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Funded by the Department of Veterans Affairs Cooperative Studies Program; PACT ClinicalTrials.gov number, NCT00532493 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a position paper by the American Academy of Sleep Medicine (AASM) has highlighted a contradictory study [33] and downgraded its recommendation for prazosin, but still considers it to be the first-line pharmacological choice [34].”
From Nightmare Disorder and Isolated Sleep Paralysis (2021) · cites this paper as [33]
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J.-D., Ding, Y.-S., Henry, S., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
RetractedThe PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Bush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Self-citationRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
Self-citation
Research works printed but not linked: 3
- Guy W. CDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
- Frisch MB. Manual and treatment guide for the Quality of Life Inventory (QOLI). Minneapolis: Pearson Assessments 1994.
- The Management of Posttraumatic Stress Disorder Working Group. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.
Cited by
Items 301–355 of 355
Twice Daily Prazosin and Valproic Acid in the Treatment of Flashbacks in PTSD
Fisher, K. A., Kiziah, H., & Villalba, C. L. A. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/1223292
“’s findings in a large randomized control trial that showed no significant benefit of prazosin over placebo [5].”
BackgroundAdherence with Treatment for Sleep Apnea in Patients with Comorbid Post-traumatic Stress Disorder
Jindal, R. D., & Garg, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-93146-9_20
Coquemont, C., Georges, C., Massoubre, B., Massoubre, C., & Boulliat, C. (2022) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20221003.12
Introduction and synopsis of chapters
Altschuler, E. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98815-5.00004-5
Altschuler, E. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98815-5.00007-0
Pharmacologic Treatment of Insomnia
Mishima, K. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_137-1 · Cited by 1
Toxicity Profile Study of Antihypertensive Drug Prazosin in Pregnant Wistar Rats
Kumar, Y. G., Dharmamoorthy, G., Devhare, L., Gunjal, S. D., Deshpande, M., & Ritika, R. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is6.1974 · Cited by 6
Barbosa-Méndez, S., & Salazar‐Juárez, A. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01247-7
“However, prazosin decreased suicidal ideation in patients with post-traumatic stress disorder (McCall et al., 2018; Raskind et al., 2018), which suggests that prazosin could reduce suicidal behavior during cocaine withdrawal.”
Case reports in psychopharmacology
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4421-1
Trauma- and Stressor-Related Disorders
Suryadevara, U., Bruijnzeel, D. M., Wenger, J., Hitching, R., & Fenn, H. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-53976-3_13
Chapter 58. Treatment of Insomnia
Krystal, A. D. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as58
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd06
Chapter 51. Treatment of Posttraumatic Stress Disorder
Nemeroff, C. B., Rosen, V., & Ortiz, N. F. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as51
Tiwari, V., & Rueda-Lara, M. A. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197667859.003.0018
Manejo farmacológico no transtorno de Estresse Pós Traumático
Resende, A. B., Madruga, M. M. D. O., Castelhano, H. R. D. J. A., Lacerda, F. M. C., Belato, S., Rojas, E. V. D. O. B., de Oliveira, A. L., da Cruz, E. F., Salge, C. B. F., & Plachi, F. D. C. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n11p4284-4296
Current Treatments for Anxiety and Trauma-Related Disorders
Szuhany, K. L., Feldman, B. H., Malgaroli, M., & Simon, N. M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0042
Effectiveness of Pharmacological Treatment for PTSD: A Systematic Review
Vyas, D., Tripathi, S., & Goel, D. (2025) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7432-0.ch022
Perinatal Post-traumatic Stress Disorder and Sleep Pathology
Thomson, M., & Sharma, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-95948-6_8
Yu, Q., Wu, J., Peng, S., & Huang, C. (2025) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2025.08.958
Siderides, C., Cebeci, C., Riccardi, J., McKenzie, K., McFadden, N. R., Robitsek, R. J., Laskowski, R. A., & Bliton, J. (2025) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004785
Welche Arten von Forschung gibt es?
Kerckhoff, A., & Fesel, S. S. (2025) · Springer eBooks · doi:10.1007/978-3-662-71506-2_2
Canada, A. (2025) · Nursing Clinics of North America · doi:10.1016/j.cnur.2025.09.004
Chen, S. S., Chang, Y.-C., Yu, C., Hsieh, T.-Y., & Sung, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238302
“In clinical practice, a wide range of α -blockers is available, and some have demonstrated symptom improvement in certain psychiatric disorders [6,7], underscoring their complex effects on neuropsychiatric conditions.”
Wellington, N. J., Quigley, B. L., Bouças, A. P., Dutton, M., Can, A., Lagopoulos, J., & Kuballa, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120791
DISTURBO DA STRESS POST TRAUMATICO: TERAPIE ATTUALI E NUOVE FRONTIERE DI RICERCA
LACERRA, M. (2022) · Electronic Theses and Dissertations Repository (University of Pisa)
Hinkka, I., & Lehtisalo, M. (2024) · UTUPub (University of Turku)
The Scarred Circuitry of Fear: A Computational–Clinical Synthesis of PTSD NeurobiologyPreprint
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7
Radtke, A., Tchopev, Z. N., Cushman, P., Kang, J., Burch, A., Scheuller, H. S., & Brock, M. S. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-025-00016-0
“The DSM-5 requires that coexisting mental disorders and mental conditions do not adequately explain the predominant complaint interventions, such as prazosin, are also an option, particularly in cases stemming from trauma, although their effec - tiveness varies [20, 37, 38].”
The Scarred Circuitry of Fear: A Computational–Clinical Synthesis of PTSD NeurobiologyPreprint
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7.2
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7.3
Feingold, D., Quiquempoix, M., Remadi, M., Sipahimalani, G., Lahutte, B., Léger, D., Gomez-Mérino, D., Chennaoui, M., & Saguin, E. (2026) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.70038
“12,13 Current treatments only partially alleviate TRNs, and pharmacological options such as prazosin show mixed evidence across military populations, 14 – 16 underscoring the need to clarify sustaining mechanisms to guide effective interventions.”
Gaudette, E. V. (2020) · TSpace (University of Toronto) · Cited by 1
Sipahimalani, G., Roseau, J.-B., Feingold, D., Remadi, M., Lhermitte, C., Houssany-Pissot, S., Defontaine, D., Gignoux-Froment, F., Annette, S., & Saguin, E. (2026) · L Encéphale · doi:10.1016/j.encep.2026.01.004
Saguin, E. (2023) · theses.fr (ABES) · doi:10.70675/820b81b5zdd45z43a6zb36az8344c91402bd · Cited by 1
Olten, B., Dunlop, B. W., & McCall, W. V. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250029
The perspectives of personalizing therapy for PTSD based on coping strategies
Zakurazhnaya, V., Tsurina, A. M., Zimina, P. A., Khamidova, A., Riabinina, D. A., Vasilishena, T. E., Andreyuk, D., Reznik, A. M., Kostyuk, G. P., & Fedotova, J. (2026) · International Review of Psychiatry · doi:10.1080/09540261.2026.2645597
“In contrast, another investigation indicated that the α1-blocker prazosin did not sufficiently alleviate trauma-related outcomes (Raskind et al., 2018).”
Clinical update on the use of prazosin for night-time symptoms of PTSD
Maguire, P. A., Bastiampillai, T. J., Allison, S. C., Wilkes, F., & Looi, J. C. (2026) · Australasian Psychiatry · doi:10.1177/10398562261448412
The Neurophysiology of Depression, Interactions Between the Brainstem and Cerebral Cortex
Ashford, J. W. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_25
Spezifisch Belastungs-assoziierte Störungen
Kapfhammer, H., Eberle, D. J., & Maercker, A. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_71-2
Prazosin for post-traumatic nightmares: A clinical audit in acute public psychiatric unit patients
Heeney, C., Rainbow, S., Isaacs, A. N., & Keks, N. A. (2026) · Australasian Psychiatry · doi:10.1177/10398562261458938
Roussange, F., Gide, J., Tournois, J., Cailleret, M., Boland, A., Battail, C., Deleuze, J., Polvèche, H., Auboeuf, D., Brockmann, K., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.102977 · Cited by 1
Once-Nightly Pregabalin for Co-Occurring Nightmares, Poor Sleep, and Headaches: A Case Series
Bates, J., Rosin, S., & Tobin, J. A. (2026) · Nature and Science of Sleep · doi:10.2147/nss.s600495
“For example, prazosin, one of the most used pharmacologic treatments for trauma-related nightmares, failed to demonstrate efficacy in reducing nightmare frequency or improving sleep quality in a large randomized controlled trial of veterans with PTSD. 6 This finding highlights the need for additional therapeutic optio…”
Pharmakotherapeutische Behandlung der Posttraumatischen Belastungsstörung
Schmidt, U., Schellong, J., Bergemann, N., Frommberger, U., & Roepke, S. (2026) · Trauma und Gewalt · doi:10.21706/tg-20-3-190
Gonzalez‐Torres, C., Seens, H., & Sharma, V. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2725862
Orexin receptor antagonists attenuate acute stress-induced disruptions in sleep states
Lilly, K., Perez, S. M., & Lodge, D. J. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1898419
“Prazosin, an alpha-1 adrenergic receptor antagonist, is commonly used for PTSD-associated nightmares; however, its effects on global PTSD symptoms and overall sleep quality are mixed (Lappas et al., 2024; Lipinska et al., 2016; Raskind et al., 2018; Mellman et al., 2022).”
Robertson, B., Wargo, E. F., & Fay, J. (2026) · Frontiers in Sleep · doi:10.3389/frsle.2026.1941077
Trauma, Hyperarousal, and Sleep: Neurobehavioral Pathways in Affective Disorders
Marano, G., Acanfora, M., Conci, L., Traversi, G., Napolitano, D., Mazza, O., & Mazza, M. (2026) · Behavioral Sciences · doi:10.3390/bs16101764
“Key supporting evidence includes CBT-I across mental disorders (Hertenstein et al., 2022), IRT for post-trauma nightmares (Casement & Swanson, 2012; Prguda et al., 2023), and mixed evidence for prazosin in PTSD-related nightmares (Raskind et al., 2018).”
Epigenetic mechnisms involved in posttraumatic stress disorder
CHEISHVILI, D., Yaakov, H., & Shrira, A. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00027-x
BARIANI, E. R., Ferreira, G. L. M., Simionato, R. B., Silva, R. G. V. D., Silva, A. L. D., & Rodrigues, C. (2026) · Artefactum · doi:10.23900/artefactum.v25i12.019
Wei, Y., Shi, Z., & Shen, Y. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2751476
Kalinovskii, A. P., Osmakov, D. I., Logashina, Y. A., Andreev, Y. A., & Трухан, В. М. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111397
Metadata
- Authors
- Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D.
- Affiliations
- University of Washington (US)
- From the Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center (M.A.R., E.R.P., H.A.H., K.L.H., M.M.) and the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine (M.A.R., E.R.P., M.M.), Seattle; VA Cooperative Studies Program Coordinating Center, Palo Alto (B.C., M.-C.S., Y.L.), VA Long Beach Healthcare System, Department of Human Behavior, University of California, Irvine (C.R.), the Department of Health Research...
- Howard University (US)
- United States Department of Veterans Affairs (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 507-517
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2789959403
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 44 · 2023: 25 · 2022: 49 · 2021: 39 · 2020: 51 · 2019: 40 · 2018: 28
- FWCI
- 46.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- VA Cooperative Studies Program.
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- prazosin, post-traumatic stress disorder, military veterans, nightmares, chronic PTSD, alpha-blockers, sleep quality, blood pressure, adverse effects, PTSD pharmacotherapy, sleep disorders, sleep quality index, Clinician-Administered PTSD Scale, Clinical Global Impression of Change, dose escalation
- MeSH terms
- Adult, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Dreams, Female, Hospitals, Veterans, Humans, Male, Middle Aged, Prazosin, Psychiatric Status Rating Scales, Psychotherapy, Sleep, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, United States, Veterans, Treatment Failure, Adrenergic alpha-1 Receptor Antagonists, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.